Allergan scores a PhIII win with an acne drug now headed to the FDA
Allergan is teeing up a new drug application for sarecycline after investigators reported that the acne treatment scored promising data in two Phase III studies.
Highlighted in Allergan’s $AGN recent pipeline review as one of its late-stage drugs in the medical aesthetics and dermatology group, sarecycline is a narrow spectrum antibiotic designed to eliminate acne. The drug is partnered with Paratek $PRTK, which saw its shares shoot up 18% this morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.